Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798686 | 1.00 | CPN1 (0.54) | CPN1CPB2KMT2AKDM4EMAPT | |
| SCHEMBL1800254 | 0.89 | SLC6A1 (0.48) | CPN1CPB2KMT2AKDM4EMAPT | |
| SCHEMBL1800252 | 0.89 | SLC6A1 (0.48) | CPN1CPB2KMT2AKDM4EMAPT | |
| SCHEMBL24740306 | 0.89 | SLC6A1 (0.48) | CPN1CPB2KMT2AKDM4EMAPT | |
| SCHEMBL1062937 | 0.86 | CPN1 (0.62) | CPN1CPB2KMT2AKDM4EMAPT | |
| SCHEMBL1309969 | 0.86 | CPN1 (0.62) | CPN1CPB2KMT2AKDM4EMAPT | |
| SCHEMBL24190465 | 0.81 | CPN1 (0.49) | CPN1CPB2KMT2AKDM4EMAPT | |
| SCHEMBL11695337 | 0.79 | ALOX5 (0.47) | EPHX1ALOX5 | |
| SCHEMBL23194396 | 0.79 | ALOX5 (0.47) | EPHX1ALOX5 | |
| SCHEMBL14889755 | 0.79 | ALOX5 (0.47) | EPHX1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | CPN1 2426/4885CPB2 2223/4885KMT2A 3600/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | CPN1 3087/4885CPB2 3192/4885KMT2A 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.